CORRELATION BETWEEN METABOLIC SYNDROME AND SARCOIDOSIS

ATS
2016

J VIDENOVIC-IVANOV V MIHAILOVIC-VUCINIC S FILIPOVIC-STEPIC M STJEPANOVIC

UNIVERSITY CLINIC FOR LUNG DISEASES , BELGRADE

M OMCIKUS

INTRODUCTION

Figure 2.

RESULTS

ABSTRACT

PARAMETER

MEAN

BMI( kg/m)
WAIST(cm )
TRIGLICERIDE
mmol/L
HDLHolesterol
mmol/L
FASTING GLUCOSE
mmol/L
SYSTOLIC
PRESSURE(mmHg)
DIASTOLIC
PRESSURE(mmHg)
%FAT

AIM
Analyze the influence of steroid therapy in
sarcoidosis patients with metabolic syndrome
and without metabolic syndrome.

SD

38.3659
97.0909
1.79021

16.04291
13.27571
0.94854

88
88
88

10.030

12.000

7.920

10.000

1.5425

0.61527

88

6.7102

3.88051

88

131.1364

16.16594

88

81.2500

11.01853

88

49.8230

17.75811

6.350

8.000
6.440

5.340
5.200

6.000

4.000
2.000
0.000
NO STEROIDE
5mg

Figure 1.
TRG/HDL Metabolic syndrome

30mg

Steroide doses

P<0.01

NON METABOLIC SYNDROME

METABOLIC SYNDROME

METHOD
Analysed 88( 69 female /19 male )patients with
previously diagnosed sarcoidosis.
Metabolic syndrome have been obtained in 39 / 88
patients. Distribution by numbers of participants
regardless corticosteroid therapy were as followed:
1. 27 participants did not received steroid therapy.
2. 32 participants received 5-10mg prednisone daily
or alternatively
3. 29 participants were treated with 20-30mg
prednisone daily.
.

2.356

CONCLUSION

2.343

2.500

2.000

Means of Trg/HDL Hol ratio

The impact of corticosteroid therapy in biopsy

proven sarcoidosis with or without metabolic
syndrome, analysed in 88 patients, 69
female/19male). Method: 39/88 patients have
metabolic syndrome. 20-30 mg prednisone /
daily were administered on 29 patients; 32
patients were treated with 5-10mg steroid
daily, 27 patients were not treated with steroid
therapy. Results: Statistically significant
difference was found in lipid metabolism
between patients with/without metabolic
syndrome (F=2629.336;df1=4;df2=80; p<0.01)
and between the doses of steroid therapy and
glucose fasting (F=52.743;df=6;df2=82;p<0.01 )
Conclusion:Lower doses of steroid therapy
have the influence on metabolism of lipids and
carbohydrates in sarcoidosis patients.

IFG (mmol/l)-Metabolic syndrome - Steroid

dose

TABLE 1. METABOLIC AND ANTHROPOMETRIC VARIABLES

Means of fasting glucose

Sarcoidosis is granulomatous multisystemic

disease with chronic course and unknown
aetiology. Therapy options depend on
numberes parameters including comorbidities.
Corticosteroid are the most implementing
therapy.

1.221
1.500

1.093
0.964

1.137

1.000

0.500

Higher doses of steroid therapy which have been

administering in short time, during one month,
have no influence on the metabolism of lipids and
carbohydrates.

0.000
NO STEROIDE

Aditional remarks is potential correlation

5mg
30mg

Steroide doses

p>0.05

NON METABOLIC SYNDROME

between BMI and

METABOLIC SYNDROME

sarcoidosis.